Metoclopramide Hydrochloride Accord Healthcare Ireland (Metoclopramide Hydrochloride Anhydrous)

Metoclopramide Hydrochloride is indicated for conditions involving nausea, delayed gastric emptying, and reflux, acting through dopamine antagonism in the chemoreceptor trigger zone and gastrointestinal tract.

• Nausea and vomiting: reduces frequency and severity of acute and chronic nausea and vomiting episodes.
• Gastroparesis: accelerates gastric emptying and improves related symptoms such as early satiety.
• Gastro‑oesophageal reflux disease (GERD): enhances lower esophageal sphincter tone and reduces reflux episodes.
• Post‑operative nausea and vomiting (PONV): provides prophylaxis and treatment after surgical procedures.

• Metoclopramide Hydrochloride exerts its effect by competitively blocking dopamine D2 receptors in the chemoreceptor trigger zone of the medulla and in the gastrointestinal smooth muscle. This antagonism removes inhibitory dopaminergic tone, promoting acetylcholine release, which enhances antral contractility and accelerates gastric emptying. In the central nervous system, D2 blockade reduces the stimulus for nausea and vomiting and also increases lower esophageal sphincter pressure, contributing to reflux control.

Metoclopramide Hydrochloride may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Drowsiness: mild sedation that may affect alertness.
• Fatigue: general feeling of tiredness.
• Restlessness: uneasy feeling often described as akathisia.
• Diarrhea: loose stools occurring during therapy.
• Headache: mild to moderate head pain.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Extrapyramidal symptoms: involuntary muscle contractions such as dystonia or tremor.
• Tardive dyskinesia: persistent involuntary movements, especially with prolonged treatment.
• Neuroleptic malignant syndrome: rare but severe reaction with fever, rigidity and autonomic instability.
• Seizures: rare occurrence of convulsive episodes.

When prescribing Metoclopramide Hydrochloride, several safety considerations should be observed to minimize risk.

• Assess renal function: dose adjustment may be needed in renal impairment.
• Monitor for extrapyramidal symptoms: discontinue if severe movement disorders develop.
• Avoid in patients with known hypersensitivity: discontinue at first sign of allergic reaction.
• Use caution in pregnancy: risk category unknown, weigh benefits against potential risks.
• Review concomitant CNS depressants: may enhance sedation and respiratory depression.
• Store at room temperature: keep in original container, protect from moisture and light.

Metoclopramide Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Anticholinergic agents: may diminish pro‑kinetic effect.
• MAO inhibitors: risk of hypertensive crisis or serotonin excess.
• CNS depressants (e.g., opioids, benzodiazepines): increased sedation and respiratory depression.
• Dopamine agonists (e.g., levodopa, bromocriptine): antagonistic effect reducing therapeutic benefit.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise metoclopramide plasma levels.
• Anticholinergic antihistamines: additive anticholinergic burden.
• SSRIs: potential for enhanced serotonergic activity and rare serotonin syndrome.